New hope for rare bone marrow cancer: drug combo trial launches
NCT ID NCT07340138
First seen Jan 17, 2026 · Last updated May 25, 2026 · Updated 23 times
Summary
This early-stage study tests whether adding pelabresib to the standard drug ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and measure drug levels. The goal is to find a safe dose for future studies, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGKamogawa, Chiba, 296-8602, Japan
-
Novartis Investigative Site
RECRUITINGSapporo, Hokkaido, 0030006, Japan
-
Novartis Investigative Site
RECRUITINGKamakura, Kanagawa, 247-8533, Japan
-
Novartis Investigative Site
RECRUITINGBunkyo Ku, Tokyo, 1138431, Japan
-
Novartis Investigative Site
RECRUITINGChūō, Yamanashi, 409-3898, Japan
-
Novartis Investigative Site
RECRUITINGKumamoto, 862-8655, Japan
Conditions
Explore the condition pages connected to this study.